G-Protein–Coupled Receptors as Signaling Targets for Antiplatelet Therapy
Authors:
- Susan S. SmythSSSusan S. Smyth
- Donna S. WoulfeDWDonna S. Woulfe
- Jeffrey I. WeitzJWJeffrey I. Weitz
- Christian GachetCGChristian Gachet
- Pamela B. ConleyPCPamela B. Conley
- Shaun G. GoodmanSGShaun G. Goodman
- Matthew T. RoeMRMatthew T. Roe
- Athan KuliopulosAKAthan Kuliopulos
- David J. MoliternoDMDavid J. Moliterno
- Patricia A. FrenchPFPatricia A. French
- Steven R. SteinhublSSSteven R. Steinhubl
- Richard C. BeckerRBRichard C. Becker
- 1 April 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 29 (4) , 449-457
Abstract
Platelet G protein–coupled receptors (GPCRs) initiate and reinforce platelet activation and thrombus formation. The clinical utility of antagonists of the P2Y 12 receptor for ADP suggests that other GPCRs and their intracellular signaling pathways may represent viable targets for novel antiplatelet agents. For example, thrombin stimulation of platelets is mediated by 2 protease-activated receptors (PARs), PAR-1 and PAR-4. Signaling downstream of PAR-1 or PAR-4 activates phospholipase C and protein kinase C and causes autoamplification by production of thromboxane A 2 , release of ADP, and generation of more thrombin. In addition to ADP receptors, thrombin and thromboxane A 2 receptors and their downstream effectors—including phosphoinositol-3 kinase, Rap1b, talin, and kindlin—are promising targets for new antiplatelet agents. The mechanistic rationale and available clinical data for drugs targeting disruption of these signaling pathways are discussed. The identification and development of new agents directed against specific platelet signaling pathways may offer an advantage in preventing thrombotic events while minimizing bleeding risk.Keywords
This publication has 72 references indexed in Scilit:
- European PerspectivesCirculation, 2008
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-IIThe Lancet, 1997
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Aggregation of Blood Platelets by Adenosine Diphosphate and its ReversalNature, 1962